PINNACLE PCL Trademark

Trademark Overview


On Monday, February 28, 2022, a trademark application was filed for PINNACLE PCL with the United States Patent and Trademark Office. The USPTO has given the PINNACLE PCL trademark a serial number of 97287809. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, June 13, 2024. This trademark is owned by Ultragenyx Pharmaceutical Inc.. The PINNACLE PCL trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science

General Information


Serial Number97287809
Word MarkPINNACLE PCL
Filing DateMonday, February 28, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, June 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 23, 2023

Trademark Statements


NOT AVAILABLE"PCL"
Goods and ServicesResearch and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 3, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameUltragenyx Pharmaceutical Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Party NameUltragenyx Pharmaceutical Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events


Event DateEvent Description
Thursday, March 3, 2022NEW APPLICATION ENTERED
Thursday, March 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 12, 2022ASSIGNED TO EXAMINER
Wednesday, December 14, 2022NON-FINAL ACTION WRITTEN
Wednesday, December 14, 2022NON-FINAL ACTION E-MAILED
Wednesday, December 14, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 9, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 9, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 9, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 3, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 23, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 23, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 20, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, December 20, 2023SOU EXTENSION 1 FILED
Wednesday, December 20, 2023SOU EXTENSION 1 GRANTED
Friday, December 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 13, 2024SOU TEAS EXTENSION RECEIVED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 13, 2024SOU EXTENSION 2 GRANTED
Thursday, June 13, 2024SOU EXTENSION 2 FILED
Friday, August 2, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, August 2, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 2, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, August 2, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, December 12, 2024SOU TEAS EXTENSION RECEIVED